STTK
Shattuck·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
RSI Overbought
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About STTK
Shattuck Labs, Inc.
A clinical-stage biotech company pioneering bi-functional fusion proteins as a new class of biologic medicine for cancer and autoimmune disease
Biological Technology
05/09/2016
10/09/2020
NASDAQ Stock Exchange
44
12-31
Common stock
500 W. 5th Street, Suite 1200, Austin, TX 78701
--
Shattuck Labs, Inc., was incorporated in Delaware on May 9, 2016. The company is an innovative clinical-stage biotechnology company dedicated to the development of double-sided fusion proteins as an entirely new biomedical product.
Company Financials
EPS
STTK has released its 2025 Q3 earnings. EPS was reported at -0.14, versus the expected -0.15, beating expectations. The chart below visualizes how STTK has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
STTK has released its 2025 Q3 earnings report, with revenue of 1.00M, reflecting a YoY change of -66.63%, and net profit of -10.06M, showing a YoY change of 39.69%. The Sankey diagram below clearly presents STTK's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
